Menu
Recruiting NCT06982573

The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With ESRD

No phase Interventional End-Stage Renal Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Effects of applying magnetic stimulation.
Who it may be relevant to
Registry conditions: End-Stage Renal Disease. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With End-Stage Renal Disease (ESRD)

Overview

To determine the effectiveness of magnetic stimulation application on alleviating back pain and maintaining muscle mass in patients with end-stage renal disease.

Interventions

  • Device Effects of applying magnetic stimulation
    The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients with End-Stage Renal Disease (ESRD)

Primary outcome measures

  • Visual Analogue Sclae (VAS) [Time frame: 7 days before intervention/1 day after intervention/1 month after intervention]
Secondary outcome measures (4)
  • Short Physical Performance Battery (SPPB) [Time frame: 7 days before intervention/1 day after intervention/1 month after intervention]
  • The World Health Organization (WHOQOL-BREF) [Time frame: 7 days before intervention/1 day after intervention/1 month after intervention]
  • 3D Motion Capture [Time frame: 7 days before intervention/1 day after intervention/1 month after intervention]
  • Dual Energy X-ray Absorptionmetry (DEXA) [Time frame: 7 days before intervention/1 day after intervention/1 month after intervention]

Eligibility criteria

Inclusion criteria

  • Adults aged 19 years or older
  • Patients diagnosed with end-stage renal failure and receiving dialysis treatment more than three times a week
  • Back pain intensity of 4 points or higher on the visual analogue scale (VAS)
  • Those with cognitive function that can clearly indicate NRS with a score of 23 points or higher, the criterion for determining cognitive impairment on the Mini Mental State Examination (MMSE) \[14\]
  • Those who voluntarily decided to participate in this clinical trial after receiving a detailed explanation and fully understanding it and gave written consent to comply with the precautions

Exclusion criteria

  • If the pain is due to trauma
  • If it is difficult to participate in the study due to serious mental illness (e.g. schizophrenia, bipolar disorder, etc.) or psychological instability.
  • Patients with severe neurological illness (e.g. stroke, severe dementia, etc.).
  • Those with poor general condition due to unstable cardiovascular, digestive, respiratory, or endocrine systems, or severe internal medical illness such as systemic infection
  • Patients participating in other therapeutic clinical trials or those who have participated in other therapeutic clinical trials within the past 30 days (observational studies are not relevant)
  • If there are contraindications to magnetic stimulation
  • Patients with implanted medical devices (e.g. pacemakers)
  • Metal objects are inserted into the skull
  • A wound on the skin at the attachment site
  • History of epilepsy
  • Cervical pain or musculoskeletal disease
  • Pregnant and lactating women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

South Korea · 1 center
  • CHA Bundang Medical Center, CHA University — Seongnam-si

Identifiers

NCT: NCT06982573 · 2025-01-031

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗